CombiGene’s business concept is to develop effective gene therapies for treatment of difficult-to-treat diseases for which adequate treatment methods are currently lacking. The company intends to take its candidate drugs through the phases of preclinical development and initial clinical studies under its own management, and subsequently continue development and commercialization under its own management or in collaboration with other partners. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Nasdaq First North and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se . For further information, please visit www.combigene.com.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme
Company Details
- Employees
- 6
- Founded
- -
- Address
- Skeppsbron 38, Stockholm,111 30,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- combigene.com
- Keywords
- Bioteknik, Genteknik, Neurovetenskap.
- HQ
- Stockholm
Combigene Questions
Combigene's website is combigene.com
Combigene's LinkedIn profile is https://se.linkedin.com/company/combigene
Combigene has
6 employees.
View email and phone details for 6
employees at Combigene.
Combigene's industry is
Biotechnology Research
Combigene's top competitors are
Rezdiffra™ (Resmetirom) Hcp,
Bioarctic,
Zyneyro,
Redsense Medical,
Parabilis Medicines,
Lipidor Ab,
Oblique Therapeutics Ab (Publ.),
Di Akademi,
Epigenica,
Stayble Therapeutics.
Combigene's categories are Biotechnology Research
Combigene's founding year is 2008
